Source:http://linkedlifedata.com/resource/pubmed/id/14583893
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
5
|
| pubmed:dateCreated |
2003-10-29
|
| pubmed:commentsCorrections | |
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Oct
|
| pubmed:issn |
1071-9164
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
9
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
347-9
|
| pubmed:dateRevised |
2007-11-15
|
| pubmed:meshHeading |
pubmed-meshheading:14583893-Cardiotonic Agents,
pubmed-meshheading:14583893-Clinical Trials as Topic,
pubmed-meshheading:14583893-Drug Design,
pubmed-meshheading:14583893-Heart Failure,
pubmed-meshheading:14583893-Humans,
pubmed-meshheading:14583893-Receptors, Endothelin,
pubmed-meshheading:14583893-Technology, Pharmaceutical
|
| pubmed:year |
2003
|
| pubmed:articleTitle |
The dilemma of drug development for heart failure: when is the time to initiate large clinical trials?
|
| pubmed:publicationType |
Editorial,
Comment
|